Background <p>Atorvastatin is a lipophilic statin that exhibits pleiotropic effects beyond cholesterol (Chol) reduction. Sortilin is one of the factors related to insulin sensitivity and Lipid metabolism. Sortilin, as a cell surface and intracellular receptor, is a main member of the vacuolar protein sorting 10 proteins (VPS10Ps) family.</p> Objective <p>This study aimed to evaluate the effects of atorvastatin consumption on blood levels of sortilin, glycemic, and Lipid indices in patients with type 2 diabetes mellitus (T2DM).</p> Methods <p>A randomized controlled trial was conducted among 60 participants, who were grouped into three distinct categories: patients with T2DM, pre-treatment with atorvastatin 40&#xa0;mg/day into group 1 (<i>n</i> = 30); patients with T2DM, after treatment with atorvastatin 40&#xa0;mg/day, group 2; and post-treatment and healthy controls, group 3. Patients used atorvastatin for 3 months.</p> Results <p>FBS, HbA1c, LDL-C, TG, T-Chol, insulin, HOMA-IR, and sortilin concentrations in group 1 were significantly higher than those in group 3. But there was no significant difference in HDL-C content between the two groups. FBS, HbA1c, HDL-C, insulin, HOMA-IR, and sortilin concentrations in the diabetic group 2 were notably&#xa0;higher than those in group 3. But the serum levels of LDL-C in group 2 receiving atorvastatin are lower than those in group 3. The two groups had no notable difference in TG and T-Chol serum levels. Atorvastatin significantly attenuated the blood levels of FBS, HbA1c, TG, T-Chol, LDL-C, HOMA-IR, and sortilin. But the serum levels of HDL-C and insulin notably increased by atorvastatin.</p> Conclusion <p>Atorvastatin can attenuate diabetic complications by improving glycemic indices, lowering TG, LDL-C, and sortilin concentrations, and enhancing HDL-C levels.</p> Trial registration <p>This randomized clinical trial was registered at IRCT.ir on 2023-12-12 (Registration Code: IRCT20231122060137N1).</p>